A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes

Summary

This study aims to investigate the efficacy and safety of tirzepatide in participants with type 2 diabetes (T2D) compared to other existing treatment options when treatment is initiated early.

Timeline

Start

2022-08-01

Primary completion

2025-10-21

Completion

2027-11

Outcome

Met primary endpoint

paper Tirzepatide was superior to ICC for mean changes from baseline to 2 years in HbA1c (-1.99 percentage points [95% CI, -2.12 to -1.87 PMID 42184419 ↗

Publications

• Del Prato S, Heine RJ, Perez Manghi FC, Hsia SH, Gomez-Valderas E, Zeytinoglu M, Razzoli E, Kiljanski J, Sharma P, Knights A, Thieu VT. Tirzepatide Versus Intensified Conventional Care After 2 Years of Treatment in Early Type 2 Diabetes : A Randomized Clinical Trial. Ann Intern Med. 2026 May 26. doi: 10.7326/ANNALS-25-05602. Online ahead of print.

Drugs

Indications